Physician profile
David P Hill
NPI 1447228135
$2,408.09
in general payments reported to CMS, 2019-2025
44 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $310 · 2021: $595 · 2022: $393 · 2023: $490 · 2024: $236 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.60 |
| Education | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $176.06 | 2020-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $174.51 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $161.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.70 | 2021-2024 | Ofev, Jardiance |
| Astellas Pharma US INC | $131.82 | 2019-2023 | Myrbetriq |
| Lilly USA, LLC | $130.08 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $129.37 | 2019-2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $105.80 | 2019-2023 | Rexulti |
| Novo Nordisk INC | $101.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $99.85 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $80.21 | 2019-2020 | |
| Abbvie INC. | $63.99 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.35 | 2022-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $57.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.47 | 2022-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.